US2991227A - Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system - Google Patents

Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system Download PDF

Info

Publication number
US2991227A
US2991227A US619925A US61992556A US2991227A US 2991227 A US2991227 A US 2991227A US 619925 A US619925 A US 619925A US 61992556 A US61992556 A US 61992556A US 2991227 A US2991227 A US 2991227A
Authority
US
United States
Prior art keywords
stimulation
dimethyl
iodide
compositions
dimethyl phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US619925A
Inventor
Chen Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parke Davis and Co LLC
Original Assignee
Parke Davis and Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US318761A external-priority patent/US2778772A/en
Application filed by Parke Davis and Co LLC filed Critical Parke Davis and Co LLC
Priority to US619925A priority Critical patent/US2991227A/en
Application granted granted Critical
Publication of US2991227A publication Critical patent/US2991227A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • This invention relates to compositions useful for stimulating the autonomic ganglia containing as the effective ingredient l,l-dimethyl-4-phenyl-piperidinium iodide.
  • the latter compound has the physiological property of exerting a stimulating eflect on both the sympathetic and parasympathetic ganglia. This newly discovered property makes it possible to use the compound for the laboratory determination of the eifectiveness of potential ganglionic blocking agents.
  • the autonomic ganglion system is composed of the sympathetic ganglia and the parasympathetic ganglia. Stimulation of the sympathetic ganglia causes release of an epinephrine-like substance by the postganglionic fibers while stimulation of the parasympathetic ganglia causes release of acetyl choline by both the preand post-ganglionic fibers.
  • compositions of the present invention are prepared by dissolving 1,l-dimethyl-4-phenylpiperidinium iodide in water, isotonic saline or isotonic glucose and sterilizing the resulting solution by heat or by Zeitz filtration. It will also be appreciated that the compositions can be prepared under aseptic conditions using sterile ingredients.
  • the solutions which are the most useful in the detection of ganglionic disorders are those containing 0.5 to 5 milligrams of the quaternary halide compound in each milliliter of the solution. These solutions are administered by the parenteral route and preferably intravenously.
  • the physiological efiect of the compositions of the invention can be demonstrated on the sympathetic ganglia using pentobarbitalized cats and measuring the contraction of the nictating membrane caused by injection of a measured quantity of the composition.
  • 200 micrograms per kg. of 1,1-dimethyl-4-phenylpiperidinium iodide give the same degree of response as 5 micrograms per kg. of epinephrine acting through the effector cells.
  • the effects of l,1-dimethyl-4-phenylpiperidinium iodide are completely blocked by the administration of milligrams per kg. of the ganglionic blocking agent, triethylammonium chloride. Under these same conditions the stimulating efiect of epinephrine was not blocked because it does not act upon the ganglia.
  • compositions of the invention exert a stimulating eflect upon the ganglion-like material of the adrenal medulla and are therefore useful in determining the ability of the adrenal medulla to produce epinephrine.
  • the difierence in the response obtained under these two conditions is a measure of the adrenal medullas ability to produce epinephrine.
  • compositions of the invention are relatively nontoxic.
  • the LD of 1,1-dimethyl-4-phenylpiperidinium iodide is 17 milligrams per kg. in mice given intraperitoneally.
  • Example 1 6 g. of l-methyl-4-phenylpiperidine is dissolved in 100 ml. of absolute alcohol and treated with 10 g. of methyl iodide. The solution is allowed to stand for one hour at room temperature and is then concentrated to approximately ml. in a steam bath. The residue is diluted with ether and chilled. The crystals are filtered oil and recrystallized in a mixture of ethanol and ether. The product is 1,l-dimethyl-4phenylpiperidinium iodide having a melting point of 167-169 C.
  • 1,l-dimethyl-4phenylpiperidinium iodide is dissolved in 100 ml. of isotonic salt solution which contains :a total of 850 mg. of sodium chloride. 1 ml. por tions of the solution are placed in 2 ml. glass ampoules and the ampoules sealed. The ampouled material is sterilized in a steam autoclave for twenty minutes at to C. The material in the ampoules is assayed by determining its effect on the sympathetic and parasympathetic ganglia using the methods described above. Each ampoule should contain approximately 1 milligram of 1,1- dimethyl-4-phenylpiperidinium iodide.
  • Example 2 50 milligrams of 1,l-dimethyl-4-phenylpiperidinium iodide is dissolved in 100 ml. of distilled water. liter portions of the solutions are placed in glass ampoules and the ampoules sealed. The ampouled material is sterilized by heating in a steam autoclave for fifteen minutes at fifteen pounds pressure steam. The material in the ampoules is assayed by the methods mentioned above. Each ampoule should contain 0.5 milligram of 1,l-di methyl-4-phenylpiperidinium iodide.
  • a composition for the stimulation of the sympathetic and parasympathetic ganglia comprising an aqueous solution containing 0.5 to 5 milligrams per milliliter of 1,1-dimethyl-4-phenylpiperidinium iodide.
  • a composition for the stimulation of the sympathetic and parasympathetic ganglia consisting of a sterile, aqueous, isotonic, saline solution containing 1 milligram per milliliter of 1,1 dimethyl 4 phenylpiperidinium iodide.
  • a composition for the simulation of the sympathetic One milli- 3 and parasympathetic ganglia consisting of a sterile, aqueous solution containing 0.5 milligram per milliliter of 1,1- dimethyl-4-phenylpiperidinium iodide.

Description

United States PatentOf 2 991,227 r DIMETHYL PHIENYL PIPERIDINIUM IODIDE COM- POSITIONS FOR STIMULATION OF THE AUTO- NOMIC GANGLION SYSTEM Graham Chen, Detroit, Mich, assignor to Parke, Davis & Company, Detroit, Mich., a corporation of Michigan No Drawing. Original application Nov. 4, 1952, Ser. No. 318,761. Divided and this application Nov. 2, 1956, Ser. No. 619,925
4 Claims. (Cl. 167-84.5)
This invention relates to compositions useful for stimulating the autonomic ganglia containing as the effective ingredient l,l-dimethyl-4-phenyl-piperidinium iodide. I have discovered that the latter compound has the physiological property of exerting a stimulating eflect on both the sympathetic and parasympathetic ganglia. This newly discovered property makes it possible to use the compound for the laboratory determination of the eifectiveness of potential ganglionic blocking agents.
The autonomic ganglion system is composed of the sympathetic ganglia and the parasympathetic ganglia. Stimulation of the sympathetic ganglia causes release of an epinephrine-like substance by the postganglionic fibers while stimulation of the parasympathetic ganglia causes release of acetyl choline by both the preand post-ganglionic fibers.
In many clinical conditions the normal functions of the autonomic ganglion system are impaired or stimulated and it is of great value to the practitioner to be able to ascertain whether this is due to the ganglion system itself or some other cause. In order to test the functioning of the autonomic ganglion system it is necessary to utilize some substance which will disturb in a controllable fashion the normal operation of the sympathetic and parasympathetic ganglia. It is known that nicotine is capable of stimulating both the sympathetic and parasympathetic ganglia. However, nicotine is a relatively weak stimulant and is unsatisfactory and dangerous to use clinically due to the depressive, toxic and paralyzing effects which it produces. Epinephrine and norepinephrine exert a stimulating effect upon the eflector cells but they do not act on either the sympathetic or parasympathetic ganglia.
The compositions of the present invention are prepared by dissolving 1,l-dimethyl-4-phenylpiperidinium iodide in water, isotonic saline or isotonic glucose and sterilizing the resulting solution by heat or by Zeitz filtration. It will also be appreciated that the compositions can be prepared under aseptic conditions using sterile ingredients. The solutions which are the most useful in the detection of ganglionic disorders are those containing 0.5 to 5 milligrams of the quaternary halide compound in each milliliter of the solution. These solutions are administered by the parenteral route and preferably intravenously.
The physiological efiect of the compositions of the invention can be demonstrated on the sympathetic ganglia using pentobarbitalized cats and measuring the contraction of the nictating membrane caused by injection of a measured quantity of the composition. When tested in accordance with this method 200 micrograms per kg. of 1,1-dimethyl-4-phenylpiperidinium iodide give the same degree of response as 5 micrograms per kg. of epinephrine acting through the effector cells. The effects of l,1-dimethyl-4-phenylpiperidinium iodide are completely blocked by the administration of milligrams per kg. of the ganglionic blocking agent, triethylammonium chloride. Under these same conditions the stimulating efiect of epinephrine was not blocked because it does not act upon the ganglia.
The physiological eifect on the parasympathetic ganglia 2,991,227. Patented July 4, 1.961.
can be demonstrated by the increase in bladder pressure of female dogs under pentobarbital anesthesia following intravenous injection of a solution of 1,1-dimethyl-4- phenylpiperidinium iodide. In this test it only required 10 to 20 micrograms per kg. of l,1-dimethyl-4phenylpiperidiniuni iodide in order to bring about a change in bladder pressure and it was possible to block this pressure change completely by the administration of 10 milligrams per kg. of triethylammoniuni chloride.
The compositions of the invention exert a stimulating eflect upon the ganglion-like material of the adrenal medulla and are therefore useful in determining the ability of the adrenal medulla to produce epinephrine. In utilizing the compositions for this purpose one injects a measured quantity of the ganglionic stimulating agent and measures the amount of stimulation obtained with and without a ganglionic blocking agent. The difierence in the response obtained under these two conditions is a measure of the adrenal medullas ability to produce epinephrine.
The compositions of the invention are relatively nontoxic. For example, the LD of 1,1-dimethyl-4-phenylpiperidinium iodide is 17 milligrams per kg. in mice given intraperitoneally.
The invention is illustrated by the following examples.
Example 1 6 g. of l-methyl-4-phenylpiperidine is dissolved in 100 ml. of absolute alcohol and treated with 10 g. of methyl iodide. The solution is allowed to stand for one hour at room temperature and is then concentrated to approximately ml. in a steam bath. The residue is diluted with ether and chilled. The crystals are filtered oil and recrystallized in a mixture of ethanol and ether. The product is 1,l-dimethyl-4phenylpiperidinium iodide having a melting point of 167-169 C.
mg. of 1,l-dimethyl-4phenylpiperidinium iodide is dissolved in 100 ml. of isotonic salt solution which contains :a total of 850 mg. of sodium chloride. 1 ml. por tions of the solution are placed in 2 ml. glass ampoules and the ampoules sealed. The ampouled material is sterilized in a steam autoclave for twenty minutes at to C. The material in the ampoules is assayed by determining its effect on the sympathetic and parasympathetic ganglia using the methods described above. Each ampoule should contain approximately 1 milligram of 1,1- dimethyl-4-phenylpiperidinium iodide.
Example 2 50 milligrams of 1,l-dimethyl-4-phenylpiperidinium iodide is dissolved in 100 ml. of distilled water. liter portions of the solutions are placed in glass ampoules and the ampoules sealed. The ampouled material is sterilized by heating in a steam autoclave for fifteen minutes at fifteen pounds pressure steam. The material in the ampoules is assayed by the methods mentioned above. Each ampoule should contain 0.5 milligram of 1,l-di methyl-4-phenylpiperidinium iodide.
This application is a division of my co-pending applica tion Serial No. 318,761 filed November 4, 1952, now US. Patent No. 2,778,772.
What I claim is:
1. A composition for the stimulation of the sympathetic and parasympathetic ganglia comprising an aqueous solution containing 0.5 to 5 milligrams per milliliter of 1,1-dimethyl-4-phenylpiperidinium iodide.
2. A composition for the stimulation of the sympathetic and parasympathetic ganglia consisting of a sterile, aqueous, isotonic, saline solution containing 1 milligram per milliliter of 1,1 dimethyl 4 phenylpiperidinium iodide.
3. A composition for the simulation of the sympathetic One milli- 3 and parasympathetic ganglia consisting of a sterile, aqueous solution containing 0.5 milligram per milliliter of 1,1- dimethyl-4-phenylpiperidinium iodide.
4. The method of testing the effectiveness of ganglionic blocking agents, comprising administering to an experimental animal 1,1-dimethyl-4-phenylpiperidinium iodide for the laboratory determination of the effectiveness of potential ganglionic blocking agents.
References Cited in the file of this patent UNITED STATES PATENTS 2,778,772 Chen Jan. 22, 1957 '4 OTHER REFERENCES Lands: J. Pharm. and Exp. Therap., vol. 102, No. 4, August 1951, pp. 219-236. 5 Chem. Abst., 1944, pp. 744. Chem. Abst., 1950, p. 2987. Howard: Modern Drug EncycL, 5th ed., Drug Pub. 1952, pp. 1131 14.
Robinson: J. of Organic Chem., vol. 16, December 10 1951, pp. 1911-930 (C. A., vol. 46, p. 9555i).
Chem. Abst., vol. 22, 1938, p. 426.

Claims (1)

1. A COMPOSITION FOR THE STIMULATION OF THE SYMPATHITIC AND PARASYMPATHETIC GANGLIA COMPRISING AN AQUEOUS SOLUTION CONTAINING 0.5 TO 5 MILLIGRAMS PER MILLILITER OF 1,1-DIMETHYL-4-PHENYLPIPERIDINIUM IODIDE.
US619925A 1952-11-04 1956-11-02 Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system Expired - Lifetime US2991227A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US619925A US2991227A (en) 1952-11-04 1956-11-02 Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US318761A US2778772A (en) 1952-11-04 1952-11-04 Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system
US619925A US2991227A (en) 1952-11-04 1956-11-02 Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system

Publications (1)

Publication Number Publication Date
US2991227A true US2991227A (en) 1961-07-04

Family

ID=26981654

Family Applications (1)

Application Number Title Priority Date Filing Date
US619925A Expired - Lifetime US2991227A (en) 1952-11-04 1956-11-02 Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system

Country Status (1)

Country Link
US (1) US2991227A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3309274A (en) * 1962-07-23 1967-03-14 Brilliant Herbert Use of fluorescent dyes in dental diagnostic methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2778772A (en) * 1952-11-04 1957-01-22 Parke Davis & Co Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2778772A (en) * 1952-11-04 1957-01-22 Parke Davis & Co Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3309274A (en) * 1962-07-23 1967-03-14 Brilliant Herbert Use of fluorescent dyes in dental diagnostic methods

Similar Documents

Publication Publication Date Title
Todd et al. Duration of ischemia influences the development and resolution of ischemic brain edema.
CN101938904A (en) Intrathecal treatment of neuropathic pain with a2ar agonists
AU2013203252A1 (en) Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
Mitchell et al. Is prostaglandin E the neural mediator of the febrile response? The case against a proven obligatory role.
Laburn et al. Pyrogen and prostaglandin fever in the rabbit—II: Effects of noradrenaline depletion and adrenergic receptor blockade
US2778772A (en) Dimethyl phenyl piperazinium iodide compositions and process for stimulation of the autonomic ganglion system
US2991227A (en) Dimethyl phenyl piperidinium iodide compositions for stimulation of the autonomic ganglion system
Peacock et al. Rate of absorption of carcinogens and local tissue reaction as factors influencing carcinogenesis
BRPI0807928A2 (en) METHODS TO IDENTIFY A LYN KINASE ACTIVATOR, AND TO TREAT DIABETES IN A HUMAN, KIT, AND, COMPOSITION
Minton Volunteer models for predicting antiemetic activity of 5‐HT3‐receptor antagonists.
Klingman et al. Studies on severe alcohol intoxication in dogs. II. Mechanisms involved in the production of hyperglycemia, hypokalemia and hemoconcentration
US3097136A (en) Process for producing a depressant-like effect on the central nervous system
Lewis et al. The effects of intraventricular 6-hydroxydopamine on body temperature and arterial blood pressure in cats and rabbits
Qu et al. Selective sphingosine-1-phosphate receptor 1 modulation ameliorates TBI-induced neurological deficit after CCI
Dixon et al. Single‐dose, placebo‐controlled, phase I study of oral dolasetron
Figge et al. Relation of water metabolism to porphyrin incrustations in pantothenic acid-deficient rats
US3824313A (en) Topical opthalmic composition and methods of use
Wilson et al. Integration at an inhibitory interneurone: inhibition of Renshaw cells
Birkhimer et al. The neuroleptic malignant syndrome: presentation and treatment
Kandasamy et al. Prostacyclin-induced hyperthermia: implication of a protein mediator
Somberg Digitalis: neurally mediated arrhythmogenic and coronary vasoconstrictor properties
US2850428A (en) Partially depolymerized hyaluronic acid as a spreading and lipemiaclearing agent
Clark et al. Effects of centrally administered pentazocine and ethylketocyclazocine on thermoregulation in the cat
Kalas et al. The effect of vasoactive antagonists in endetoxin shock
Wong et al. Intraocular injection of prostaglandins: Modification of response to circulating bacterial endotoxin